FT827 |
Catalog No.GC32917
One-Click Copy Product Info
|
FT827 es un inhibidor selectivo y covalente de la proteasa 7 específica de ubiquitina (USP7) (Ki=4.2 ?M). FT827 se une al dominio catalítico USP7 (USP7CD; residuos 208-560) con un valor aparente de Kd de 7.8 ?M.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1959537-86-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
FT827 is a selective, covalent ubiquitin-specific protease 7 (USP7; Ki=4.2µM, Kd=7.8µM) inhibitor. FT827 can be used in cancer-related research[1-2].
In vitro, FT827 (0.1-2µM) treated MCF7 breast cancer cells for 60 minutes. FT827 specifically inhibited USP7 activity in cells and did not affect other DUBs including USP47 and USP10[2].
References:
[1] El-Hamaky AA, El-Hamamsy MH, El-Moselhy TF, et al. Therapeutic targeting of ubiquitin-specific protease 7 (USP7): Mechanistic insights, dysregulation, and advances in drug discovery. Eur J Med Chem. 2025 Oct 15;296:117872.
[2] Turnbull AP, Ioannidis S, Krajewski WW, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.
| Cell experiment [1]: | |
|
Cell lines |
MCF7 cells (human breast cancer cell line) |
|
Preparation Method |
Intact MCF7 breast cancer cells were incubated with FT827, followed by incubation with the ubiquitin active site suicide probe haemagglutinin (HA)-tagged ubiquitin bromoethyl (HA-UbC2Br). |
|
Reaction Conditions |
0.1μM; 60min |
|
Applications |
FT827 inhibited USP7 probe reactivity with IC50 of 0.1-2µM. FT827 only affected USP7, but not other deubiquitinases (DUBs) including USP47 and USP10 |
|
References: |
|
| Cas No. | 1959537-86-0 | SDF | |
| Canonical SMILES | C=CS(=O)(NC1=CC=CC=C1C2=CC=C(C(N3CCC(O)(CN(C=NC4=C5C=NN4C)C5=O)CC3)=O)C=C2)=O | ||
| Formula | C27H28N6O5S | M.Wt | 548.61 |
| Solubility | DMSO : 125 mg/mL (227.85 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8228 mL | 9.1139 mL | 18.2279 mL |
| 5 mM | 364.6 μL | 1.8228 mL | 3.6456 mL |
| 10 mM | 182.3 μL | 911.4 μL | 1.8228 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)